Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 3;13(8):e071456.
doi: 10.1136/bmjopen-2022-071456.

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

Jing Huang  1 , Juanjuan Cai  1 , Qingqing Ye  1 , Qiaoying Jiang  1 , Huan Lin  1 , Lun Wu  2
Affiliations

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

Jing Huang et al. BMJ Open. .

Abstract

Objectives: This study aimed to conduct a thorough analysis of fluid retention-associated adverse events (AEs) associated with BCR::ABL inhibitors.

Design: A retrospective pharmacovigilance study.

Setting: Food and Drug Administration Adverse Event Reporting System (FAERS) database for BCR::ABL inhibitors was searched from 1 January 2004 to 30 September 2021.

Main outcome measures: Reporting OR (ROR) and 95% CI were used to detect the signals. ROR was calculated by dividing the odds of fluid retention event reporting for the target drug by the odds of fluid retention event reporting for all other drugs. The signal was considered positive if the lower limit of 95% CI of ROR was >1. The analysis was run only considering coupled fluid retention events/BCR::ABL inhibitors with at least three cases.

Results: A total of 97 823 reports were identified in FAERS. Imatinib had the most fluid retention signals, followed by dasatinib and nilotinib, while bosutinib and ponatinib had fewer signals. Periorbital oedema (ROR=24.931, 95% CI 22.404 to 27.743), chylothorax (ROR=161.427, 95% CI 125.835 to 207.085), nipple swelling (ROR=48.796, 95% CI 26.270 to 90.636), chylothorax (ROR=35.798, 95% CI 14.791 to 86.642) and gallbladder oedema (ROR=77.996, 95% CI 38.286 to 158.893) were the strongest signals detected for imatinib, dasatinib, nilotinib, bosutinib and ponatinib, respectively. Pleural effusion, pericardial effusion and pulmonary oedema were detected for all BCR::ABL inhibitors, with dasatinib having the highest RORs for pleural effusion (ROR=37.424, 95% CI 35.715 to 39.216), pericardial effusion (ROR=14.146, 95% CI 12.649 to 15.819) and pulmonary oedema (ROR=11.217, 95% CI 10.303 to 12.213). Patients aged ≥65 years using dasatinib, imatinib, nilotinib or bosutinib had higher RORs for pleural effusion, pericardial effusion and pulmonary oedema. Patients aged ≥65 years and females using imatinib had higher RORs for periorbital oedema, generalised oedema and face oedema.

Conclusions: This pharmacovigilance study serves as a clinical reminder to physicians to be more vigilant for fluid retention-associated AEs with BCR::ABL inhibitors.

Keywords: CLINICAL PHARMACOLOGY; Leukaemia; ONCOLOGY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Age and gender subgroup analysis of pleural effusion, pericardial effusion and pulmonary oedema signals of BCR::ABL inhibitors. ROR, reporting OR.
Figure 2
Figure 2
Age and gender subgroup analysis of peripheral fluid retention-related signals with imatinib. ROR, reporting OR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment.
    Lorenzo-Esteller L, Ramos-Polo R, Pons Riverola A, Morillas H, Berdejo J, Pernas S, Pomares H, Asiain L, Garay A, Martínez Pérez E, Jiménez-Marrero S, Alcoberro L, Nadal E, Gubern-Prieto P, Gual-Capllonch F, Hidalgo E, Enjuanes C, Comin-Colet J, Moliner P. Lorenzo-Esteller L, et al. Cancers (Basel). 2024 Oct 12;16(20):3466. doi: 10.3390/cancers16203466. Cancers (Basel). 2024. PMID: 39456560 Free PMC article. Review.

References

    1. Faderl S, Talpaz M, Estrov Z, et al. . The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–72. 10.1056/NEJM199907153410306 - DOI - PubMed
    1. Hehlmann R, Hochhaus A, Baccarani M, et al. . Chronic myeloid leukaemia. Lancet 2007;370:342–50. 10.1016/S0140-6736(07)61165-9 - DOI - PubMed
    1. Noronha S, Sawyer S. Chronic myeloid leukemia: advances in diagnosis and management. JAAPA 2013;26:26–9. 10.1097/01720610-201302000-00005 - DOI - PubMed
    1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–56. - PubMed
    1. Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-Abl1-targeted TKI. Leuk Lymphoma 2018;59:1523–38. 10.1080/10428194.2017.1379074 - DOI - PubMed

Publication types

MeSH terms